Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Egetis Therapeutics AB's Enterprise Value is $328.17 Mil.
Egetis Therapeutics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-28.32 Mil. Therefore, Egetis Therapeutics AB's EV-to-OCF for today is -11.59.
The historical rank and industry rank for Egetis Therapeutics AB's EV-to-OCF or its related term are showing as below:
PDPHF'
s EV-to-OCF Range Over the Past 10 Years
Min: -20.87 Med: -5.73 Max: 0.46
Current: -12.14
During the past 13 years, the highest EV-to-OCF of Egetis Therapeutics AB was 0.46. The lowest was -20.87. And the median was -5.73.
PDPHF's EV-to-OCF is ranked better than 72.25% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs PDPHF: -12.14
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egetis Therapeutics AB (OTCPK:PDPHF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egetis Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Egetis Therapeutics AB's share price for today is $0.6353.
Egetis Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.095.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Egetis Therapeutics AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's EV-to-OCF falls into.
Egetis Therapeutics AB's current Enterprise Value is $328.17 Mil.
Egetis Therapeutics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (PDPHF) has a EV-to-OCF of -11.59 as of Aug. 09, 2026. According to the industry distribution chart, Egetis Therapeutics AB ranks #391 out of 1409 companies in the Biotechnology industry, placing it in the top 27.8%.
Is Egetis Therapeutics AB's EV-to-OCF too high?
Egetis Therapeutics AB's current EV-to-OCF is -11.59. Based on the distribution chart, Egetis Therapeutics AB ranks #391 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #391 out of 1409 companies for EV-to-OCF. This puts Egetis Therapeutics AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Egetis Therapeutics AB's current EV-to-OCF is -11.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Egetis Therapeutics AB (PDPHF) has a current EV-to-OCF of -11.59. The stock's GF Value™ is $0.51, compared to a current price of $0.64 — trading 24.6% above its estimated fair value. The current EV-to-OCF is -11.59. Egetis Therapeutics AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current EV-to-OCF is -11.59 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of $0.64 is trading 24.6% above its estimated GF Value™ of $0.51.
Key valuation signals for PDPHF:
EV-to-OCF: -11.59
GF Value™: $0.51 vs. price of $0.64 (24.6% above fair value)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
67GF Score
Get the complete analysis for PDPHF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
